Why resurrect a
relic of the past?
When it comes to cell collection for Barrett’s esophagus
Embrace the future of esophageal cell collection
EsoCheck is a swallowable balloon capsule device designed to noninvasively collect protected samples from the distal esophagus, with a pristine safety profile in nearly 30,000 patients. Samples collected with EsoCheck, when analyzed with EsoGuard biomarkers, detected Barrett’s esophagus, including short segment, with a negative predictive value of ~99%.
1-3
Join the growing list of clinicians who offer targeted cell collection with EsoCheck
1. Moinova HR, Verma S, Dumot J, Faulx A, Iyer PG, Canto MI, Wang JS, Shaheen NJ, Thota PN, Aklog L, Willis JE, Markowitz SD, Chak A. Multicenter, Prospective Trial of Nonendoscopic Biomarker-Driven Detection of Barrett’s Esophagus and Esophageal Adenocarcinoma. Am J Gastroenterol. 2024 Nov 1;119(11):2206-2214.
2.Greer KB, Blum AE, Faulx AL, Deming EM, Hricik LL, Siddiqui H, Wilson BM, Chak A. Nonendoscopic Screening for Barrett’s Esophagus and Esophageal Adenocarcinoma in At-Risk Veterans. Am J Gastroenterol. 2025 Mar 1;120(3):545-553.
3. Shaheen NJ, Othman MO, Taunk J, Chang KJ, Jaganmohan S, Yachimski PS, Fang JC, Spataro JS, Verma S, Lee VT, deGuzman BJ, Aklog L. Use of a Two-Gene Methylated DNA Biomarker Assay and Nonendoscopic Balloon for Detection of Barrett Esophagus Among High-Risk Individuals in a Screening Population. Am J Gastroenterol. 2024 Nov 26. doi: 10.14309/ajg.0000000000003238. Epub ahead of print.
4. https://www.accessdata. fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=201597
​
EsoCheck is a registered trademark of Lucid Diagnostics.